The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration. / Janitzek, Christoph M; Carlsen, Philip H R; Thrane, Susan; Khanna, Vijansh M; Jakob, Virginie; Barnier-Quer, Christophe; Collin, Nicolas; Theander, Thor G; Salanti, Ali; Nielsen, Morten A; Sander, Adam F.

In: Vaccines, Vol. 9, No. 2, 131, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Janitzek, CM, Carlsen, PHR, Thrane, S, Khanna, VM, Jakob, V, Barnier-Quer, C, Collin, N, Theander, TG, Salanti, A, Nielsen, MA & Sander, AF 2021, 'The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration', Vaccines, vol. 9, no. 2, 131. https://doi.org/10.3390/vaccines9020131

APA

Janitzek, C. M., Carlsen, P. H. R., Thrane, S., Khanna, V. M., Jakob, V., Barnier-Quer, C., Collin, N., Theander, T. G., Salanti, A., Nielsen, M. A., & Sander, A. F. (2021). The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration. Vaccines, 9(2), [131]. https://doi.org/10.3390/vaccines9020131

Vancouver

Janitzek CM, Carlsen PHR, Thrane S, Khanna VM, Jakob V, Barnier-Quer C et al. The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration. Vaccines. 2021;9(2). 131. https://doi.org/10.3390/vaccines9020131

Author

Janitzek, Christoph M ; Carlsen, Philip H R ; Thrane, Susan ; Khanna, Vijansh M ; Jakob, Virginie ; Barnier-Quer, Christophe ; Collin, Nicolas ; Theander, Thor G ; Salanti, Ali ; Nielsen, Morten A ; Sander, Adam F. / The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration. In: Vaccines. 2021 ; Vol. 9, No. 2.

Bibtex

@article{32e37656efba491e94bb68f2af0374fd,
title = "The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration",
abstract = "Capsid-like particle (CLP) displays can be used to enhance the immunogenicity of vaccine antigens, but a better understanding of how CLP vaccines are best formulated and delivered is needed. This study compared the humoral immune responses in mice elicited against two different vaccine antigens (a bacterial protein and a viral peptide) delivered on an AP205 CLP platform using six different adjuvant formulations. In comparison to antibody responses obtained after immunization with the unadjuvanted CLP vaccine, three of the adjuvant systems (neutral liposomes/monophosphoryl lipid A/quillaja saponaria 21, squalene-in-water emulsion, and monophosphoryl lipid A) caused significantly increased antibody levels, whereas formulation with the three other adjuvants (aluminum hydroxide, cationic liposomes, and cationic microparticles) resulted in similar or even decreased antibody responses. When delivering the soluble bacterial protein in a squalene-in-water emulsion, 4-log lower IgG levels were obtained compared to when the protein was delivered on CLPs without the adjuvant. The AP205 CLP platform promoted induction of both IgG1 and IgG2 subclasses, which could be skewed towards a higher production of IgG1 (aluminum hydroxide). Compared to other routes, intramuscular administration elicited the highest IgG levels. These results indicate that the effect of the external adjuvant does not always synergize with the adjuvant effect of the CLP display, which underscores the need for empirical testing of different extrinsic adjuvants.",
author = "Janitzek, {Christoph M} and Carlsen, {Philip H R} and Susan Thrane and Khanna, {Vijansh M} and Virginie Jakob and Christophe Barnier-Quer and Nicolas Collin and Theander, {Thor G} and Ali Salanti and Nielsen, {Morten A} and Sander, {Adam F}",
year = "2021",
doi = "10.3390/vaccines9020131",
language = "English",
volume = "9",
journal = "Vaccines",
issn = "2076-393X",
publisher = "MDPI AG",
number = "2",

}

RIS

TY - JOUR

T1 - The immunogenicity of capsid-like particle vaccines in combination with different adjuvants using different routes of administration

AU - Janitzek, Christoph M

AU - Carlsen, Philip H R

AU - Thrane, Susan

AU - Khanna, Vijansh M

AU - Jakob, Virginie

AU - Barnier-Quer, Christophe

AU - Collin, Nicolas

AU - Theander, Thor G

AU - Salanti, Ali

AU - Nielsen, Morten A

AU - Sander, Adam F

PY - 2021

Y1 - 2021

N2 - Capsid-like particle (CLP) displays can be used to enhance the immunogenicity of vaccine antigens, but a better understanding of how CLP vaccines are best formulated and delivered is needed. This study compared the humoral immune responses in mice elicited against two different vaccine antigens (a bacterial protein and a viral peptide) delivered on an AP205 CLP platform using six different adjuvant formulations. In comparison to antibody responses obtained after immunization with the unadjuvanted CLP vaccine, three of the adjuvant systems (neutral liposomes/monophosphoryl lipid A/quillaja saponaria 21, squalene-in-water emulsion, and monophosphoryl lipid A) caused significantly increased antibody levels, whereas formulation with the three other adjuvants (aluminum hydroxide, cationic liposomes, and cationic microparticles) resulted in similar or even decreased antibody responses. When delivering the soluble bacterial protein in a squalene-in-water emulsion, 4-log lower IgG levels were obtained compared to when the protein was delivered on CLPs without the adjuvant. The AP205 CLP platform promoted induction of both IgG1 and IgG2 subclasses, which could be skewed towards a higher production of IgG1 (aluminum hydroxide). Compared to other routes, intramuscular administration elicited the highest IgG levels. These results indicate that the effect of the external adjuvant does not always synergize with the adjuvant effect of the CLP display, which underscores the need for empirical testing of different extrinsic adjuvants.

AB - Capsid-like particle (CLP) displays can be used to enhance the immunogenicity of vaccine antigens, but a better understanding of how CLP vaccines are best formulated and delivered is needed. This study compared the humoral immune responses in mice elicited against two different vaccine antigens (a bacterial protein and a viral peptide) delivered on an AP205 CLP platform using six different adjuvant formulations. In comparison to antibody responses obtained after immunization with the unadjuvanted CLP vaccine, three of the adjuvant systems (neutral liposomes/monophosphoryl lipid A/quillaja saponaria 21, squalene-in-water emulsion, and monophosphoryl lipid A) caused significantly increased antibody levels, whereas formulation with the three other adjuvants (aluminum hydroxide, cationic liposomes, and cationic microparticles) resulted in similar or even decreased antibody responses. When delivering the soluble bacterial protein in a squalene-in-water emulsion, 4-log lower IgG levels were obtained compared to when the protein was delivered on CLPs without the adjuvant. The AP205 CLP platform promoted induction of both IgG1 and IgG2 subclasses, which could be skewed towards a higher production of IgG1 (aluminum hydroxide). Compared to other routes, intramuscular administration elicited the highest IgG levels. These results indicate that the effect of the external adjuvant does not always synergize with the adjuvant effect of the CLP display, which underscores the need for empirical testing of different extrinsic adjuvants.

U2 - 10.3390/vaccines9020131

DO - 10.3390/vaccines9020131

M3 - Journal article

C2 - 33562114

VL - 9

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 2

M1 - 131

ER -

ID: 257032795